Genetic and epigenetic changes of genes on chromosome 3 in human urogenital tumors

Biopolymers and Cell

Volumn 27, Issue 1, 2011, Pages 25-35

  Gordiyuk, V V ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

Author keywords

Cancer; Human chromosome 3; Molecular oncomarker

Indexed keywords

MOLECULAR MARKER;

CARCINOGENESIS; CHROMOSOME 3; EPIGENETICS; GENE FUNCTION; HUMAN; REVIEW; SIGNAL TRANSDUCTION; UROGENITAL TRACT TUMOR;

EID: 79952502864     PISSN: 02337657     EISSN: 19936842     Source Type: Journal    
DOI: 10.7124/bc.00007E     Document Type: Review

References (99)

1. Lubinski J., Hadaczek P., Podolski J., Toloczko A., Sikorski A., McCue P., Druck T., Huebner K. Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas. Cancer Res.1994. 54, N 14. P. 3710-3713.
2. Gordiyuk V. V. Genetic and epigenetic changes in malignant cells of tumors of urogenital organs Biopolym. Cell. 2010. 26, N 6. P. 450-460.
3. van Gils W., Kilic E., Bruggenwirth H. T., Vaarwater J., Verbiest M. M., Beverloo B., van Til-Berg M. E., Paridaens D., Luyten G. P., de Klein A. Regional deletion and amplification on chromosome 6 in a uveal melanoma case without abnormalities on chromosomes 1p, 3 and 8. Melanoma Res. 2008. 18, N 1. P. 10-15.
4. Darai-Ramqvist E., Sandlund A., Muller S., Klein G., Imreh S., Kost-Alimova M. Segmental duplications and evolutionary plasticity at tumor chromosome break-prone regions. Genome Res. 2008. 18, N 3. P. 370-379.
5. Wang X., Zheng B., Zhang R. R., Li S., Chen X., Mulvihill J. J., Lu X., Pang H., Liu H. Automated analysis of fluorescent in situ hybridization (FISH) labeled genetic biomarkers in assisting cervical cancer diagnosis. Technol. Cancer Res. Treat. 2010. 9, N 3. P. 231-242.
6. Yoshimoto T., Matsuura K., Karnan S., Tagawa H., Nakada C., Tanigawa M., Tsukamoto Y., Uchida T., Kashima K., Aki-zuki S., Takeuchi I., Sato F., Mimata H., Seto M., Moriyama M. High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. J. Pathol. 2007. 213, N 4. P. 392-401.
7. Hadaczek P., Podolski J., Toloczko A., Kurzawski G., Sikor- ski A., Rabbitts P., Huebner K., Lubinski J. Losses at 3p common deletion sites in subtypes of kidney tumours: histopatho-logical correlations. Virchows Arch. 1996. 429, N 1. P. 37-42.
8. Durkin S. G., Ragland R. L., Arlt M. F., Mulle J. G., Warren S. T., Glover T. W. Replication stress induces tumor-like micro-deletions in FHIT/FRA3B. Proc. Natl Acad. Sci. USA. 2008. 105, N 1. P. 246-251.
9. Hintzy M. C., Camparo P., Vasiliu V., Peyromaure M., Viåil- lefond A. Renal carcinoma associated with MiTF/TFE translocation: report of six cases in young adults. Prog. Urol. 2008. 18, N 5. P. 275-280.
10. Cody N. A., Ouellet V., Manderson E. N., Quinn M. C., Filali- Mouhim A., Tellis P., Zietarska M., Provencher D. M., Mes-Masson A. M., Chevrette M., Tonin P. N. Transfer of chromo- some 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene. 2007. 26, N 4. P. 618-632.
11. Hong F. Z., Wang B., Li H. M., Liew C. T. Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas. Zhonghua Bing Li Xue Za Zhi. 2005. 34, N 5. P. 257-261.
12. Fouts R. L., Sandusky G. E., Zhang S., Eckert G. J., Koch M. O., Ulbright T. M., Eble J. N., Cheng L. Down-regulation of fragile histidine triad expression in prostate carcinoma. Cancer. 2003. 97, N 6. P. 1447-1452.
13. Cross N. A., Chandrasekharan S., Jokonya N., Fowles A., Hamdy F. C., Buttle D. J., Eaton C. L. The expression and regulation of ADAMTS-1,.4,.5,.9, and.15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate. 2005. 63, N 3. P. 269-275.
14. Banham A. H., Beasley N., Campo E., Fernandez P. L., Fidler C., Gatter K., Jones M., Mason D. Y., Prime J. E., Trougouboff P., Wood K., Cordell J. L. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 2001. 61, N 24. P. 8820-8829.
15. Taylor B. S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B. S., Arora V. K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J. E., Wilson M., Socci N. D., Lash A. E., Heguy A., Eastham J. A., Scher H. I., Reuter V. E., Scardino P. T., Sander C., Sawyers C. L., Gerald W. L. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010. 18, N 1. P. 11-22.
16. Kanjanavirojkul N., Limpaiboon T., Patarapadungkit N., Yuenyao P., Pairojkul C. Chromosome 3p alterations in northeastern Thai women with cervical carcinoma Asian. Pac. J. Cancer Prev. 2005. 6, N 4. P. 501-504.
17. Ki K. D., Lee S. K., Tong S. Y., Lee J. M., Song D. H., Chi S. G. Role of 5'-CpG island hypermethylation of the FHIT gene in cervical carcinoma. J. Gynecol. Oncol. 2008. 19, N 2. P. 117-122.
18. Kashuba V. I., Skripkina I. Ia., Saraev D. V., Gordiiuk V. V., Vinnitskaia A. B., Tsyba L. A., Pogrebnoi P. V., Blinov V. M., Zabarovskii E. R., Ryndich A. V. Identification of changes in gene loci potentially associated with cervical cancer using NotI microarrays. Ukr. Biokhim. Zhur. 2006. 78, N 2. P. 113-120.
19. Gordiyuk V. V., Gerashchenko G. V., Skrypkina I.Ya, Simonchuk O. V., Pavlova T. V., Ugrin D. D., Manzhura E. P., Vakulenko G. O., Zabarovsky E. R., Rynditch A. V., Kashuba V. I. Identification of chromosome 3 epigenetic and genetic abnormalities and gene expression changes in ovarian cancer. Biopolym. Cell. 2008. 24, N 4. P. 223-332.
20. Loginov V. I., Bazov I. V., Khodyrev D. S., Pronina I. V., Ka- zubskaia T. P., Ermilova V. D., Gar’kavtseva R. F., Zbarov-skii E. R., Braga E. A. Human chromosome 3P regions of putative tumor-suppressor genes in renal, breast, and ovarian carcinomas. Genetika. 2008. 44, N 2. P. 250-256.
21. Angeloni D. Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. Brief. Funct. Genomic Proteomic. 2007. 6, N 1. P. 19-39.
22. Pfeifer G. P., Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc). 2005. 70, N 5. P. 576-583.
23. Shaheduzzaman S., Vishwanath A., Furusato B., Cullen J., Chen Y., Bañez L., Nau M., Ravindranath L., Kim K. H., Mohammed A., Chen Y., Ehrich M., Srikantan V., Sesterhenn I. A., McLeod D., Vahey M., Petrovics G., Dobi A., Srivastava S. Silencing of Lactotransferrin expression by methylation in prostate cancer progression. Cancer. Biol. Ther. 2007. 6, N 7. P. 1088-1095.
24. Loginov V. I., Khodyrev D. S., Pronina I. V., Kazubskaia T. P., Ermilova V. D., Gar’kavtseva R. F., Braga E. A. Methylation of promoter region of RASSF1A gene and frequencies of allelic imbalances in chromosome 3 critical regions are correlated with progression of clear cell renal cell carcinoma. Mol. Biol. (Mosk). 2009. 43, N 3. P. 429-438.
25. Awakura Y., Nakamura E., Ito N., Kamoto T., Ogawa O. Methylation-associated silencing of TU3A in human cancers Int. J. Oncol. 2008. 33, N 4. P. 893-899.
26. Li J., Wang F., Haraldson K., Protopopov A., Duh F. M., Geil L., Kuzmin I., Minna J. D., Stanbridge E., Braga E., Kashuba V. I., Klein G., Lerman M. I., Zabarovsky E. R. Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res. 2004. 64, N 18. P. 6438-6443.
27. Rubio-Del-Campo A., Salinas-Sanchez A. S., Sanchez-San- chez F., Gimenez-Bachs J. M., Donate-Moreno M. J., Pastor-Navarro H., Carrion-López P., Escribano J. Implications of mismatch repair genes hMLH1 and hMSH2 in patients with sporadic renal cell carcinoma. BJU Int. 2008. 102, N 4. P. 504-509.
28. Arai E., Ushijima S., Tsuda H., Fujimoto H., Hosoda F., Shi- bata T., Kondo T., Imoto I., Inazawa J., Hirohashi S., Kanai Y. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome. Clin. Cancer Res. 2008. 14, N 17. P. 5531-5539.
29. Senchenko V., Liu J., Braga E., Mazurenko N., Loginov W., Seryogin Y., Bazov I., Protopopov A., Kisseljov F. L., Kashu-ba V., Lerman M. I., Klein G., Zabarovsky E. R. Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas. Oncogene. 2003. 22, N 19. P. 2984-2992.
30. Lai H. C., Lin Y. W., Chang C. C., Wang H. C., Chu T. W., Yu M. H., Chu T. Y. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecol. Oncol. 2007. 104, N 3. P. 629-635.
31. Zhang H., Zhang S., Cui J., Zhang A., Shen L., Yu H. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust. NZJ Obstet. Gynaecol. 2008. 48, N 5.-P 505-509.
32. Kwong J., Lee J. Y., Wong K. K., Zhou X., Wong D. T., Lo K. W., Welch W. R., Berkowitz R. S., Mok S. C. Candidate tumor suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia. 2006. 8, N 4. P. 268-278.
33. Birch A. H., Quinn M. C., Filali-Mouhim A., Provencher D. M., Mes-Masson A. M., Tonin P. N. Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol. Carcinog. 2008. 47, N 1. P. 56-65.
34. de Caceres I., Battagli C., Esteller M., Herman J. G., Dulaimi E., Edelson M. I., Bergman C., Ehya H., Eisenberg B. L., Cairns P. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004. 64, N 18. P. 6476-6481.
35. Nykopp T. K., Rilla K., Sironen R., Tammi M. I., Tammi R. H., Hamalainen K., Heikkinen A. M., Komulainen M., Kosma V. M., Anttila M. Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content. BMC Cancer. 2009. 12, N 9. P. 143.
36. Salama M. E., Worsham M. J., DePeralta-Venturina M. Malignant papillary renal tumors with extensive clear cell change: a molecular analysis by microsatellite analysis and fluorescence in situ hybridization. Arch. Pathol. Lab. Med. 2003. 127, N 9. P. 1176-1181.
37. Guo Z., Wu F., Asplund A., Hu X., Mazurenko N., Kisseljov F., Ponten J., Wilander E. Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. Mod. Pathol. 2001. 14, N 2. P. 54-61.
38. Muller I., Urban K., Pantel K., Schwarzenbach H. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia Ann. N. Y. Acad. Sci. 2006. 1075. P. 222-229.
39. Haudenschild D. R., Curtiss S. B., Moseley T. A., Reddi A. H. Generation of interleukin-17 receptor-like protein (IL-17RL) in prostate by alternative splicing of RNA. Prostate. 2006. 66, N 12. P. 1268-1274.
40. Balachandar V., Kumar B. L., Sasikala K., Manikantan P., Sangeetha R., Devi S. M. Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer patients J. Zhejiang Univ. Sci. B. 2007. 8, N 9. P. 638-646.
41. Dasgupta S., Chakraborty S. B., Roy A., Roychowdhury S., Panda C. K. Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients. Mol. Pathol. 2003. 56, N 5. P. 263-269.
42. Braga E., Senchenko V., Bazov I., Loginov W., Liu J., Ermilova V., Kazubskaya T., Garkavtseva R., Mazurenko N., Kisse- ljov F., Lerman M. I., Klein G., Kisselev L., Zabarovsky E. R. Critical tumor-suppressor gene regions on chromosome 3P in major human epithelial malignancies: allelotyping and quantitative real-time PCR. Int. J. Cancer. 2002. 100, N 5. P. 534-541.
43. Rokman A., Baffoe-Bonnie A. B., Gillanders E., Fredriksson H., Autio V., Ikonen T., Gibbs K. D., Jr., Jones M., Gildea D., Freas-Lutz D., Markey C., Matikainen M. P., Koivisto P. A., Tammela T. L., Kallioniemi O. P., Trent J., Bailey-Wilson J. E., Schleutker J. Hereditary prostate cancer in Finland: fine- mapping validates 3p26 as a major predisposition locus. Hum Genet. 2005. 116, N 1-2. P. 43-50.
44. Voelter-Mahlknecht S., Ho A. D., Mahlknecht U. Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene Int. J. Mol. Med. 2005. 16, N 4. P. 589-598.
45. Villagra A., Cheng F., Wang H. W., Suarez I., Glozak M., Maurin M., Nguyen D., Wright K. L., Atadja P. W., Bhalla K., Pinilla-Ibarz J., Seto E., Sotomayor E. M. The histone deace- tylase HDAC11 regulates the expression of interleukin 10 and immune tolerance Nat. Immunol. 2009. 10, N 1. P. 92-100.
46. Wilting S. M., de Wilde J., Meijer C. J., Berkhof J., Yi Y., van Wieringen W. N., Braakhuis B. J., Meijer G. A., Ylstra B., Snijders P. J., Steenbergen R. D. Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer Genes Chromosomes Cancer. 2008. 47, N 10. P. 890-905.
47. Goyama S., Nitta E., Yoshino T., Kako S., Watanabe-Okochi N., Shimabe M., Imai Y., Takahashi K., Kurokawa M. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization Leukemia. 2010. 24, N 1. P. 81-88.
48. Andersson S., Sowjanya P., Wangsa D., Hjerpe A., Johansson B., Auer G., Gravitt P. E., Larsson C., Wallin K. L., Ried T., Heselmeyer-Haddad K. Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears Am. J. Pathol. 2009. 175, N 5. P. 1831-1847.
49. Woenckhaus J., Steger K., Sturm K., Kunstedt K., Franke F. E., Fenic I. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer Virchows Arch. 2007. 450, N 4. P. 387-395.
50. Sattler H. P., Lensch R., Rohde V., Zimmer E., Meese E., Bonkhoff H., Retz M., Zwergel T., Bex A., Stoeckle M., Wullich B. Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate. 2000. 45, N 3. P. 207-215.
51. Jung V., Kindich R., Kamradt J., Jung M., Muller M., Schulz W. A., Engers R., Unteregger G., Stockle M., Zimmermann R., Wullich B. Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer. Mol. Cancer Res. 2006. 4, N 3. P. 169-176.
52. Peters D. G., Kudla D. M., Deloia J. A., Chu T. J., Fairfull L., Edwards R. P., Ferrell R. E. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiol. Biomarkers Prev. 2005. 14, N 7. P. 1717-1723.
53. Feng Q., Balasubramanian A., Hawes S. E., Toure P., Sow P. S., Dem A., Dembele B., Critchlow C. W., Xi L., Lu H., McIn- tosh M. W., Young A. M., Kiviat N. B. Detection of hyper-methylated genes in women with and without cervical neoplasia J. Natl Cancer Inst. 2005. 97, N 4. P. 273-282.
54. Choi C. H., Lee K. M., Choi J. J., Kim T. J., Kim W. Y., Lee J. W., Lee S. J., Lee J. H., Bae D. S., Kim B. G. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Lett. 2007. 255, N 1 P. 26-33.
55. Anedchenko E. A., Kiseleva N. P., Dmitriev A. A., Kiselev F. L., Zabarovskii E. R., Senchenko V. N. Tumor suppressor gene RBSP3 in cervical carcinoma: copy number and transcriptional level. Mol. Biol. (Mosk). 2007. 41, N 1. P. 86-95.
56. Kuroki T., Trapasso F., Yendamuri S., Matsuyama A., Alder H., Mori M., Croce C. M. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma Cancer Res. 2003. 63, N 13. P. 3724-3728.
57. Zhang L., Volinia S., Bonome T., Calin G. A., Greshock J., Yang N., Liu C. G., Giannakakis A., Alexiou P., Hasegawa K., Johnstone C. N., Megraw M. S., Adams S., Lassus H., Huang J., Kaur S., Liang S., Sethupathy P., Leminen A., Simossis V. A., Sandaltzopoulos R., Naomoto Y., Katsaros D., Gimotty P. A., DeMichele A., Huang Q., Butzow R., Rustgi A. K., Weber B. L., Birrer M. J., Hatzigeorgiou A. G., Croce C. M., Coukos G. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer Proc. Natl Acad. Sci. USA. 2008. 105, N 19. P. 7004-7009.
58. Theodore S. C., Rhim J. S., Turner T., Yates C. MiRNA 26a expression in a novel panel of African American prostate cancer cell lines Ethn. Dis. 2010. 20, N 1. P. 96-100.
59. Wang G., Wang Y., Feng W., Wang X., Yang J. Y., Zhao Y., Wang Y., Liu Y. Transcription factor and microRNA regulation in androgen-dependent and.independent prostate cancer cells. BMC Genomics. 2008. 16, N 9. P. 22.
60. Juan D., Alexe G., Antes T., Liu H., Madabhushi A., Delisi C., Ganesan S., Bhanot G., Liou L. S. Identification of a microRNA panel for clear-cell kidney cancer Urology. 2010. 75, N 4. P. 835-841.
61. Shen J., DiCioccio R., Odunsi K., Lele S. B., Zhao H. Novel genetic variants in miR-191 gene and familial ovarian cancer BMC Cancer. 2010. 18, N 10. P. 47.
62. Lui W. O., Pourmand N., Patterson B. K., Fire A. Patterns of known and novel small RNAs in human cervical cancer Cancer Res. 2007. 67, N 13. P. 6031-6043.
63. Altuvia Y., Landgraf P., Lithwick G., Elefant N., Pfeffer S., Aravin A., Brownstein M. J., Tuschl T., Margalit H. Clustering and conservation patterns of human microRNAs Nucl. Acids Res. 2005. 33, N 8. P. 2697-2706.
64. Goatly A., Bacon C. M., Nakamura S., Ye H., Kim I., Brown P. J., Ruskonå-Fourmestraux A., Cervera P., Streubel B., Banham A. H., Du M. Q. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control Mod. Pathol. 2008. 21, N 7. P. 902-911.
65. Hua K., Din J., Cao Q., Feng W., Zhang Y., Yao L., Huang Y., Zhao Y., Feng Y. Estrogen and progestin regulate HIF-1alpha expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway Oncol. Rep. 2009. 21, N 4. P. 893-898.
66. Lee S., Garner E. I., Welch W. R., Berkowitz R. S., Mok S. C. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma Gynecol. Oncol. 2007. 106, N 2. P. 311-317.
67. Fenwick C., Na S. Y., Voll R. E., Zhong H., Im S. Y., Lee J. W., Ghosh S. A subclass of Ras proteins that regulate the degradation of IkappaB Science. 2000. 287, N 5454. P. 869-873.
68. Tokinaga K., Okuda H., Nomura A., Ashida S., Furihata M., Shuin T. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma Oncol. Rep. 2004. 12, N 4. P. 805-810.
69. Thaler S., Hahnel P. S., Schad A., Dammann R., Schuler M. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK- ERK pathway and inhibition of Akt Cancer Res. 2009. 69, N 5. P. 1748-1757.
70. Winn R. A., Van Scoyk M., Hammond M., Rodriguez K., Crossno J. T., Jr., Heasley L. E., Nemenoff R. A. Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma J. Biol. Chem. 2006. 281, N 37. P. 26943-26950.
71. Yamadori T., Baba Y., Matsushita M., Hashimoto S., Kurosaki M., Kurosaki T., Kishimoto T., Tsukada S. Bruton’s tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein Proc. Natl Acad. Sci. USA. 1999. 96, N 11. P. 6341-6346.
72. Kashuba V. I., Li J., Wang F., Senchenko V. N., Protopopov A., Malyukova A., Kutsenko A. S., Kadyrova E., Zabarovska V. I., Muravenko O. V., Zelenin A. V., Kisselev L. L., Kuzmin I., Minna J. D., Winberg G., Ernberg I., Braga E., Lerman M. I., Klein G., Zabarovsky E. R. RBSP3 (HYA22) is a tumor suppressor gene implicated in major epithelial malignancies Proc. Natl Acad. Sci. USA. 2004. 101, N 14 P. 4906-4911.
73. Otsubo T., Akiyama Y., Yanagihara K., Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis Br. J. Cancer. 2008. 98, N 4. P. 824-831.
74. Wellbrock C., Rana S., Paterson H., Pickersgill H., Brum-melkamp T., Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF PLoS One. 2008. 3, N 7. P. e2734.
75. Zhou Y., Zeng Z., Zhang W., Xiong W., Wu M., Tan Y., Yi W., Xiao L., Li X., Huang C., Cao L., Tang K., Li X., Shen S., Li G. Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway Int. J. Cancer. 2008. 123, N 9. P. 2065-2072.
76. Semba S., Trapasso F., Fabbri M., McCorkell K. A., Volinia S., Druck T., Iliopoulos D., Pekarsky Y., Ishii H., Garrison P. N., Barnes L. D., Croce C. M., Huebner K. Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential Oncogene. 2006. 25, N 20. P. 2860-2872.
77. Kurata A., Katayama R., Watanabe T., Tsuruo T., Fujita N. TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling Cancer Sci. 2008. 99, N 9. P. 1827-1834.
78. Takayama K., Horie-Inoue K., Ikeda K., Urano T., Murakami K., Hayashizaki Y., Ouchi Y., Inoue S. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells Biochem. Biophys. Res. Communs. 2008. 374, N 2. P. 388-393.
79. Chen X., Han S., Wang S., Zhou X., Zhang M., Dong J., Shi X., Qian N., Wang X., Wei Q., Shen H., Hu Z. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women Clin. Cancer Res. 2009. 15, N 1. P. 400-405.
80. Dangi-Garimella S., Yun J., Eves E. M., Newman M., Erkeland S. J., Hammond S. M., Minn A. J., Rosner M. R. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7 EMBO J. 2009. 28, N 4. P. 347-358.
81. Witwer K. W., Sisk J. M., Gama L., Clements J. E. MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response J. Immunol. 2010. 184, N 5. P. 2369-2376.
82. Willner J., Wurz K., Allison K. H., Galic V., Garcia R. L., Goff B. A., Swisher E. M. Alternate molecular genetic path ways in ovarian carcinomas of common histological types Hum. Pathol. 2007. 38, N 4. P. 607-613.
83. Balch C., Huang T. H., Brown R., Nephew K. P. The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol. 2004. 191, N 5. P. 1552-1572.
84. Hara T., Noma T., Yamashiro Y., Naito K., Nakazawa A. Quantitative analysis of telomerase activity and telomerase reverse transcriptase expression in renal cell carcinoma Urol. Res. 2001. 29, N 1. P. 1-6.
85. Bantis A., Patsouris E., Gonidi M., Kavantzas N., Tsipis A., Athanassiadou A. M., Aggelonidou E., Athanassiadou P. Telomerase RNA expression and DNA ploidy as prognostic markers of prostate carcinomas. Tumori. 2009. 95, N 6. P. 744-752.
86. Schaefer A., Jung M., Mollenkopf H. J., Wagner I., Stephan C., Jentzmik F., Miller K., Lein M., Kristiansen G., Jung K. Diagnostic and prognostic implications of microRNA profi- ling in prostate carcinoma Int. J. Cancer. 2010. 126, N 5. P. 1166-1176.
87. Wiley A., Katsaros D., Chen H., de la Longrais R. I. A., Beeghly A., Puopolo M., Singal R., Zhang Y., Amoako A., Zelterman D., Yu H. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential Cancer. 2006. 107, N 2. P. 299-308.
88. Chan M. W., Wei S. H., Wen P., Wang Z., Matei D. E., Liu J. C., Liyanarachchi S., Brown R., Nephew K. P., Yan P. S., Huang T. H. Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer Clin. Cancer Res. 2005. 11, N 20. P. 7376-7383.
89. Nanjundan M., Nakayama Y., Cheng K. W., Lahad J., Liu J., Lu K., Kuo W. L., Smith-McCune K., Fishman D., Gray J. W., Mills G. B. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer Cancer Res. 2007. 67, N 7. P. 3074-3084.
90. Grady W. M. Epigenetic events in the colorectum and in colon cancer Biochem. Soc. Trans. 2005. 33, N 4. P. 684-688.
91. Yoon M. S., Suh D. S., Choi K. U., Sol M. Y., Shin D. H., Park W. Y., Lee J. H., Jeong S. M., Kim W. G., Shin N. R. High-hro-ughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array Oncol. Rep. 2010. 24, N 4. P. 917-925.
92. Farley J., Ozbun L. L., Birrer M. J. Genomic analysis of epithelial ovarian cancer Cell Res. 2008. 18, N 5. P. 538-548.
93. Fridman E., Dotan Z., Barshack I., David M. B., Dov A., Tabak S., Zion O., Benjamin S., Benjamin H., Kuker H., Avivi C., Rosenblatt K., Polak-Charcon S., Ramon J., Rosenfeld N., Spector Y. Accurate molecular classification of renal tumors using microRNA expression J. Mol. Diagn. 2010. 12, N 5. P. 687-696.
94. Li S. S., Sharief F. S. The prostatic acid phosphatase (ACPP) gene is localized to human chromosome 3q21-q23 Genomics. 1993. 17, N 3. P. 765-766.
95. Zhang H. L., Yang L. F., Zhu Y., Yao X. D., Zhang S. L., Dai B., Zhu Y. P., Shen Y. J., Shi G. H., Ye D. W. Serum miRNA-21: Elevated levels in patients with metastatic hormone refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy Prostate. 2010. Sep 14, doi: 10.1002/pros.21246.
96. Kahn S. L., Ronnett B. M., Gravitt P. E., Gustafson K. S. Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests Cancer. 2008. 114, N 1. P. 57-64.
97. Hausler S. F., Keller A., Chandran P. A., Ziegler K., Zipp K., Heuer S., Krockenberger M., Engel J. B., Honig A., Scheffler M., Dietl J., Wischhusen J. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening Br. J. Cancer. 2010. 103, N 5. P. 693-700.
98. Skvortsova T. E., Vlassov V. V., Laktionov P. P. Binding and penetration of methylated DNA into primary and transformed human cells. Ann. N. Y. Acad. Sci. 2008. 1137. P. 36-40.
99. Jones P. A., Martienssen R. A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop Cancer Res. 2005. 65, N 24. P. 11241-11246.